Schizophrenia Research and Treatment

Research Article

Randomized Controlled Trial of Clozapine and CBT for First-Episode Psychosis with Enduring Positive Symptoms: A Pilot Study

Table 1

Demographic and intervention data.
TDZ
( 𝑛 = 1 1 ) 		TDZ+CBT
( 𝑛 = 1 2 ) 		CLZ
( 𝑛 = 1 4 ) 		CLZ+C
( 𝑛 = 1 1 )
Male (%)72.758.364.390.9
Age in years, m e a n ± S D 2 2 . 5 ± 3 . 4 2 2 . 0 ± 4 . 1 2 0 . 5 ± 3 . 5 2 0 . 8 ± 2 . 8
Schizophrenia (%)90.975.078.681.8
Schizophreniform (%)9.116.714.318.2
Delusional disorder (%)08.300
DUP in months, m e a n ± S D
  [median]		 1 4 . 9 5 ± 1 5 . 9
[ 1 2 . 0 ] 		1 5 . 5 5 ± 1 5 . 0
[ 1 2 . 3 ] 		1 4 . 6 5 ± 1 4 . 2
[ 1 2 . 0 ] 		1 3 . 7 5 ± 2 9 . 2
[ 2 . 7 ]
Max. CLZ dose (mg/day) 2 weeks pre-baseline, m e a n ± S D 3 4 0 . 1 5 ± 1 2 4 . 3 3 4 9 . 2 5 ± 1 5 1 . 7 3 2 6 . 5 5 ± 1 1 0 . 7 3 4 0 . 6 5 ± 1 0 8 . 9
Max. medication dose (mg/day) during trial, m e a n ± S D 3 1 6 . 7 5 ± 1 1 7 . 3 2 8 2 . 5 5 ± 1 6 3 . 3 2 9 8 . 5 5 ± 1 5 3 . 3 3 0 1 . 2 5 ± 1 9 5 . 8
Medication dose (mg/day) at 12 weeks, m e a n ± S D 2 6 8 . 6 5 ± 1 7 8 . 4 3 7 9 . 7 5 ± 3 4 5 . 2 3 1 5 . 1 5 ± 2 0 1 . 9 2 7 6 . 2 5 ± 2 1 1 . 6
Medication dose (mg/day) at 24 weeks, m e a n ± S D 1 4 8 . 5 5 ± 1 1 1 . 9 2 9 6 . 6 5 ± 2 7 4 . 8 3 6 4 . 6 5 ± 2 4 4 . 8 2 6 6 . 3 5 ± 1 8 2 . 6
No. of CBT sessions, m e a n ± S D ,
  [median]		 1 3 . 4 5 ± 9 . 6
[ 1 6 . 0 ] 		1 5 . 2 5 ± 6 . 5
[ 1 9 . 0 ]
Outpatient hours at 12 weeks, m e a n ± S D 1 2 . 6 5 ± 1 3 . 2 6 . 7 5 ± 7 . 0 9 . 5 5 ± 9 . 2 8 . 5 5 ± 4 . 8
Inpatient hours + home interventions at 12 weeks 2 . 1 5 ± 6 . 9 1 4 . 2 5 ± 4 2 . 0 1 . 8 5 ± 4 . 6 1 4 . 8 5 ± 2 8 . 3